Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SBRT, Atezolizumab, and Bevacizumab in Resectable Hepatocellular Carcinoma
NCT04857684Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2021
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Massachusetts General Hospital. Primary endpoint: Proportion of patients with grade 3-4 treatment-related adverse events at 6 months. Started Jun 2021; status: active, not recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04857684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857684.